sorafenib has been researched along with su 6656 in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (su 6656) | Trials (su 6656) | Recent Studies (post-2010) (su 6656) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 154 | 0 | 73 |
| Protein | Taxonomy | sorafenib (IC50) | su 6656 (IC50) |
|---|---|---|---|
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 0.1 | |
| Proto-oncogene tyrosine-protein kinase LCK | Mus musculus (house mouse) | 0.15 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 0.17 | |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 0.02 | |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | 0.13 | |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 0.77 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.1765 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 8.7 | |
| Serine/threonine-protein kinase 3 | Homo sapiens (human) | 0.11 | |
| Serine/threonine-protein kinase BRSK2 | Homo sapiens (human) | 0.1 | |
| Aurora kinase B | Homo sapiens (human) | 0.019 | |
| ALK tyrosine kinase receptor | Homo sapiens (human) | 0.85 | |
| Aurora kinase C | Homo sapiens (human) | 0.017 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Atrih, A; Auciello, FR; Gowans, GJ; Hardie, DG; Hawley, SA; Lamont, DJ; Ross, FA | 1 |
3 other study(ies) available for sorafenib and su 6656
| Article | Year |
|---|---|
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib.
Topics: Allosteric Regulation; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Binding Sites; Catalytic Domain; Cell-Free System; Enzyme Activation; HEK293 Cells; HeLa Cells; Humans; Indans; Indoles; Mutagenesis, Site-Directed; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Isoforms; Protein Serine-Threonine Kinases; Pyrimidines; Sorafenib; src-Family Kinases; Sulfonamides | 2017 |